SPECIFICS OF ACTIVE ORThOSTATIC TEST IN PATIENTS WITH CHRONIC HEART FAILURE

Aim. To reveal clinical and morphofunctional and biochemical differences among patients with chronic heart failure (CHF) with different response type on active orthostatic test (AOT).

Material and methods. Totally 63 patients with CHF included with cardiomyopathy of ischemic and non-ischemic origin mostly of II-III functional class NYHA. All patients underwent echocardiography, heart rate variability analysis (HRV) resting and during DOT, plasma levels of NT-proBNP measured with C-reactive protein, tumor necrosis factor-α, interleukines (IL)-1β,6,10. According to the dynamics of HF% in AOT, all patients were divided into 2 groups: 1st group consisted of patients with decrease of HF% in AOT, 2nd group — with increase of HF% in AOT.

Results. In patients from 2nd group we found larger heart chambers and volumes, as lower left ventricle ejection fraction comparing to the patients of the 1st group. Also in the 2nd group there were higher levels of NT-proBNP and IL-6. Resting patients of the both groups had very low values of all parameters of HRV. During AOT in the 1st group there was significant increase of HRV parameters, characterizing sympathetic and humoral systems activity. In the 2nd group the response on orthostasis was as a decrease of HRV values that characterize adreno-humoral influences, and sympathovagal index, characterizing sympathetic influence, was unchanged.

Conclusion. Population of CHF patients is heterogenic according to neurohumoral activation. Decrease of sympatho-adrenal reactivity and relative increase of parasympathic influences in active orthostasis in CHF patients probably witnesses the exhaustion of sympatho-adrenal regulation and is a marker of CHF severity.

1. Dzizinskij A, Protasov K, Kuklin S, et al. Orthostatic hypotension as a marker of cardiovascular risk in patients with arterial hypertension. Lechashhij vrach 2009. http://lvrach.ru/doctore/2009/07/10437906/ (July 2009). Russian (Дзизинский А. А., Протасов К. В., Куклин С. Г. и др. Ортостатическая гипотензия как маркер сердечнососудистого риска у больных артериальной гипертонией. Лечащий врач (электронный курс); http://lvrach.ru/doctore/2009/07/10437906/ (июль 2009 г.)).

2. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J;1996;17:354-81.

3. Papaioannou V. Heart Rate Variability and Inflammatory Indices in Cardiovascular Diseases: Different Implications of the Immunoreflex. 6th Virtual Congress of Cardiology. Bioengineering and Medical Informatics. http://www.fac.org.ar/6cvc/llave/c012/ papaioannouv.php (September — November/2009).

4. Arbolishvili G, Mareev V, Orlova Ja, et al. Heart rate variability in patients with chronic heart failure and its role in the prognosis of the disease. Kardiologia 2003;12:4-11. Russian (Арболишвили Г., Мареев В., Орлова Я. и др. Вариабельность ритма сердца при хронической сердечной недостаточности и ее роль в прогнозе заболевания. Кардиология; 2003;12:4-11).

5. Perrino C, Esposito G, Rockman H, et al. Defects in cardiomyocite function: role of betaadrenergic receptor dysfunction. Panminerva Med;2005;47(3):143-55.

6. Mihajlov VM. Heart rate variability: the experience of the practical application of the method Ivanovo: Ivan. gos. med. akademija, 2002, p. 290. Russian (Михайлов В. М. Вариабельность ритма сердца: опыт практического применения метода. Изд. второе, переработанное и доп.: Иваново: Иван. гос. мед. академия, 2002. 290 с.)

7. Shvalev V. Development of the theory of cardiac innervation during onthogenesis in health and disease. Arkh Patol;2010;72(3):61-4. Russian (Швалев В. Развитие теории об иннервации сердца в процессе онтогенеза в норме и при патологии. Архив патологии;2010;72(3):61-4).

8. Kramer R, Mason D, Braunwald E. Augmented sympathetic neurotransmitter activity in the periferal vascular bed of the patients with congestive heart failure and cardiac norepinephrine depletion. Circulation;1968;38:629-34.

9. Link J, Caldwell J. Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat Clin Pract Cardiovasc Med;2008;5:S79-86.

10. Liang C. Cardiac sympathetic nerve terminal function in congestive heart failure. Acta Pharmacol Sin;2007;28(7):921-7.

11. Olshansky B, Sabban H, Hauptman P, et al. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation;2008;118:863-71.

12. Pavlov V, Parrish W, Rosas-Ballina M, et al. Brain acetylcholinesterase activity controls systemic cytokine levels throught the cholinergic anti-inflammatory pathway. Brain Behav. Immun;2009;1(23):41-5.

13. Sato Y, Fujiwara H, Takatsu Y. Biochemical markers in heart failure. Journal of Cardiology;2012;59:1-7.

14. Mravec B. The inflammatory reflex: the role of the vagus nerve in regulation of immune functions. Cesk Fysiol;2011;60(2):57-69.

15. Kuznetsov V, Soldatova A, Enina T, et al. Biomarkers of inflammation in patients with chronic heart failure and implanted devices for cardiac resynchronization therapy. Kardiologia;2012;8:38-43. Russian (Кузнецов В., Солдатова А., Енина Т. И др. Биомаркеры воспаления у больных с хронической сердечной недостаточностью и имплантированными устройствами для сердечной ресинхронизирующей терапии. Кардиология;2012;8:38-43).